Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone

Allergy, Asthma & Clinical Immunology

Harold L Kim⁴  Jack Chiu³  Ryan Potts¹  Arunmozhi Dominic³  Gina Tsai³  Immaculate FP Nevis³  Laura Kim² 

[1]Department of Biology, University of Waterloo, Waterloo, Ontario, Canada

[2]Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada

[3]Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada

[4]525 Belmont Avenue West, Suite 205, Kitchener N2M 5E2, Ontario, Canada

关键词: Needle length;    Pediatric;    Auto-injector;    Epinephrine;    Skin-to-bone depth;    Anaphylaxis;    Food allergy;   

Others  :  1082138
DOI  :  10.1186/1710-1492-10-40

 received in 2014-06-12, accepted in 2014-07-16,  发布年份 2014

【 摘 要 】

Background

The Epipen® Jr and Allerject® 0.15 mg are currently the most commonly prescribed epinephrine auto-injectors (EAIs) for the management of anaphylaxis in pediatric patients in North America and Canada. To ensure rapid absorption, it should be administered intramuscularly into the anterolateral aspect of the thigh. We examined whether the 12.7-mm needle length of the Epipen® Jr and Allerject® 0.15 mg is adequate for delivering epinephrine intramuscularly in pediatric patients who weighed <15 kg.

Methods

Consecutive pediatric patients with food allergy weighing <15 kg who required an EAI were included. Ultrasounds of the mid-anterolateral thigh were performed under minimal (min) and maximal (max) pressure. Skin-to-muscle depth (STMD) and skin-to-bone depth (STBD) measurements were completed. Baseline characteristics were compared between patients with a STBD_max <12.7 mm vs. ≥12.7 mm. Linear regression including variables such as age, sex, body mass index (BMI) and race was performed. The proportion of patients with a STBD_max <12.7 mm was compared in those weighing <10 kg vs. 10–14.9 kg.

Results

One hundred patients were included; 29 (29%) had STBD_max <12.7 mm. Height (p = 0.02) and weight (p = 0.0002) differed significantly between the two groups. Approximately 19% of those weighing 10–14.9 kg and 60% of those <10 kg had a STBD_max <12.7 mm. In the multivariable regression analysis, BMI was found to be a significant predictor of STBD_max.

Conclusions

A large proportion of children <15 kg prescribed an EAI is at risk of having the auto-injector administered into bone. Since alternative EAIs with shorter needle lengths are not currently available, EAIs should be prescribed with appropriate counselling in this population.

【 授权许可】

   
2014 Kim et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Kim HL, Fischer D: Anaphylaxis. Allergy Asthma Clin Immunol 2011, 7(Suppl 1):S6. BioMed Central Full Text
• [2]Tejedor Alonso MA, Moro Moro M, Mugica Garcia MV, Esteban Hernandez J, Rosado Inglemo A, Vila Albelda C, Gomez Traseira C, Cardenas Contreras R, Sanz Sacristan J, Hernandez Merino A: Incidence of anaphylaxis in the city of Alcorcon (Spain): a population-based study. Clin Exp Allergy 2012, 42:578-589.
• [3]Gibbison B, Sheikh A, McShane P, Haddow C, Soar J: Anaphylaxis admissions to UK critical care units between 2005 and 2009. Anesthesia 2012, 67:833-839.
• [4]Tanno LK, Ganem F, Demoly P, Toscan CM, Bierrenbach AL: Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012, 67:783-789.
• [5]Levy MB, Goldberg MR, Nachshon L, Tabachnik E, Katz Y: Lessons from cases of mortality due to food allergy in Israel: cow’s milk protein should be considered a potentially fatal allergen. Isr Med Assoc J 2012, 14:29-33.
• [6]Fleischer DM, Perry TT, Atkins D, Wood RA, Burks AW, Jones SM, Henning AK, Stablein D, Sampson HA, Sicherer SH: Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics 2012, 130:e25-e32.
• [7]Simons FE, Ardusso RF, Dimov V, Ebisawa M, El-Gamal YM, Lockey RF, Sanchez-Borges M, Senna GE, Sheikh A, Thong BY, Worm M: World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base. Int Arch Allergy Immunol 2013, 162:193-204.
• [8]Waserman S, Watson W: Food allergy. Allergy Asthma Clin Immunol 2011, 7(Suppl 1):S7. BioMed Central Full Text
• [9]EpiPen®/EpiPen® Jr Prescribing Information. Napa, California: Dey Pharma; March 13, 2012. Available at: https://www.epipen.ca/sites/default/files/pdf/hcp/en/English_PI.pdf webcite. Accessed April 22, 2014
• [10]Allerject® 0.15 mg/ Allerject® 0.30 mg Prescribing Information. Laval, Quebec: Sanofi-Aventis Canada Inc; May 28, 2013. Available at: http://products.sanofi.ca/en/allerject.pdf webcite. Accessed July 15, 2014
• [11]Cheng A: Emergency treatment of anaphylaxis in infants and children. Paediatr Child Health 2011, 16:35-40.
• [12]Stecher D, Bulloch B, Sales J, Schaefer C, Keahey L: Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics 2009, 124:65-70.
• [13]Simons FER, Chan ES, Gu X, Simons KJ: Epinephrine for the out-of-hospital (first-aid) treatment of anaphylaxis in infants: is the ampule/syringe/needle method practical? J Allergy Clin Immunol 2001, 108:1040-1044.
• [14]Simons FER, Roberts JR, Gu X, Simons KJ: Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998, 101:33-37.
• [15]Brown AFT: Therapeutic controversies in the management of acute anaphylaxis. J Accid Emerg Med 1998, 15:89-95.
• [16]Schintler MV, Arbab E, Aberer W, Spendel S, Scharnagl E: Accidental perforating bone injury using the EpiPen® autoinjection device. Allergy 2005, 60:259-260.
• [17]Sapien R, Stein H, Padbury JF, Thio S, Hodge D: Intraosseous versus intravenous epinephrine infusion in lambs: pharmacokinetics and pharmacodynamics. Pediatr Emerg Care 1992, 8:179-183.
• [18]Orlowski JP, Porembka DT, Gallagher JM, Lockrem JD, VanLente F: Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. Am J Dis Child 1990, 144:112-117.
• [19]Shaver KJ, Adams C, Weiss SJ: Acute myocardial infarction after administration of low-dose intravenous epinephrine for anaphylaxis. CJEM 2006, 8:289-294.
• [20]Sullivan TJ: Cardiac disorders in penicillin-induced anaphylaxis. Association with intravenous epinephrine therapy. JAMA 1982, 248:2161-2162.
• [21]Canadian Medical Protective Association Newsletter. March 2010